Inclusion Criteria:

- Histologically or cytologically confirmed advanced solid tumors

- Patients who have experienced progressive disease despite of conventional anticancer
therapy. Patients who cannot expect effective treatment or prolonged survival with
conventional anticancer therapy

- Previous chemotherapy (excluding irinotecan), radiotherapy and surgical operation are
allowed if they are discontinued for at least 4 weeks prior to D0 and all adverse
events are resolved (6 weeks for nitrosoureas and mitomycin)

- Aged ≥18

- Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to
2

- A life expectancy greater than 12 weeks

- Adequate bone marrow (platelet≥100 x 109/L, hemoglobin≥10.0g/dl and ANC≥ 1.5 x 109/L,
renal (Creatinine≤1.5mg/dl) and liver function (AST/ALT/ALP ≤ 3 x upper limit of
normal and total bilirubin≤2mg/dl) and no abnormal heart and lung function However,
AST/ALT/ALP ≤ 5 x upper limit of normal for patients with liver metastases and ALP
level ≤ 5 x upper limit of normal for patients with bone metastases are allowed.

- Patients with no need of radiotherapy (except for true oncologic emergency occurring
after entry on study [e.g. acute spinal cord compression], other anticancer drugs and
immunotherapy during the trial

- Subjects must provide written informed consent prior to performance of study specific
procedures or assessments, and must be willing to comply with treatment and follow up
assessments and procedures

Exclusion Criteria:

- Patients with hematopoietic malignancies ( including leukemia, lymphoma, multiple
myeloma, myelodysplastic syndromes, myeloproliferative disorders), ileus, CNS
metastasis, and with active infections requiring parenteral or systemic
antibacterial, antiviral, or antifungal therapy. Patients with infections may
participate in this clinical trial after complete recovery or control of the
infection

- Patients with chronic malabsorption, or who have undergone total colectomy

- Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are
candidates for planned HSCT

- History of congestive heart failure, atrial arrhythmia or ventricular arrhythmia
requiring medication; Patients who had treatment for myocardial infarction or any
other acute coronary syndrome event within the past 6 months.

- Subjects who, in the investigator's opinion, cannot be treated per protocol due to
functional impairments due to any other severe co-morbid medical conditions

- Pregnant or breast-feeding patients; Women of childbearing potential without adequate
contraception (Men must use adequate contraception.)

- Subjects who have no intention of following the requirements of the protocol or the
follow-up management. Subjects who cannot be followed up regularly due to
psychological, social, family, logistic, and geographical reasons.

- Subjects who have been treated with PGP inhibitors (cyclosporine A and verapamil),
which are contraindicated medications, will have a wash-out period of 2 weeks.

- Subjects who were administered with other investigational products within 28 days
before screening.